Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Strength Cond Res ; 33(1): 217-224, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28445231

RESUMO

Jo, E, Fischer, M, Auslander, AT, Beigarten, A, Daggy, B, Hansen, K, Kessler, L, Osmond, A, Wang, H, and Wes, R. The effects of multiday vs. single pre-exercise nitrate supplement dosing on simulated cycling time trial performance and skeletal muscle oxygenation. J Strength Cond Res 33(1): 217-224, 2019-A transient augmentation in the metabolic efficiency of skeletal muscle is the purported basis for dietary nitrate supplementation amongst competitive and recreational athletes alike. Previous studies support the ergogenic effects of nitrate supplementation, as findings indicated improved microvascular blood flow, exercise economy, and performance with relatively short-term supplementation. As with most ergogenic aids, the optimum duration of supplementation before performance or competition, i.e., loading phase, is a critical determinant for efficacy. Therefore, the purpose of this study was to investigate the effects of long-term vs. single dosing nitrate supplementation on skeletal muscle oxygenation and cycling performance. In a randomized, placebo controlled, double blind, parallel design study, healthy, recreationally active men (n = 15) and women (n = 14) subjects (age = 18-29 years) completed an 8 km (5 mi) simulated cycling time trial before and after a 14-day supplementation period with either a nitrate supplement (Multi-Day Dosing Group) (n = 14) or placebo (Single Pre-Exercise Dosing Group; SD) (n = 15). Both groups consumed a single dose of the nitrate supplement 2 hours before the post-treatment time trial. In addition, skeletal muscle oxygenation was measured via near-infrared spectroscopy during each time trial. Multiday nitrate supplementation significantly decreased time to completion (p = 0.01) and increased average power (p = 0.04) and speed (p = 0.02) from pre-to post-treatment, while a single dosing produced no significant changes to these measures. There were no significant differences over time and across treatments for any other measures including muscle oxygenation variables. Overall, long-term nitrate supplementation appears to have an advantage over a single pre-exercise dosing on cycling performance and metabolic efficiency as indicated by an increase in power output with no change in oxygenation.


Assuntos
Desempenho Atlético , Ciclismo , Suplementos Nutricionais , Nitratos/administração & dosagem , Substâncias para Melhoria do Desempenho/administração & dosagem , Fenômenos Fisiológicos da Nutrição Esportiva , Adolescente , Adulto , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Masculino , Músculo Esquelético/fisiologia , Oxigênio/análise , Espectroscopia de Luz Próxima ao Infravermelho , Adulto Jovem
2.
Am J Trop Med Hyg ; 97(6): 1726-1730, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29141716

RESUMO

Hansen's Disease (HD) is a rare, chronic granulomatous infection of the skin and peripheral nerves caused by the noncultivable organism Mycobacterium leprae. Arthritis is the third most common symptom of HD. Subjects with both confirmed HD on skin biopsy and chronic arthritis were identified at the National Hansen's Disease Program (NHDP). We conducted a series of medical chart reviews and extracted and logged personally deidentified data into a database and carried out descriptive analyses. Eighteen of 261 subjects presented to the NDHP with both HD and chronic arthritis between 2001 and 2015. Among these, 16 were male, 16 were white, and 15 were residents of Louisiana. The median age at diagnosis of HD was 67 years. Ten of these subjects were diagnosed with borderline lepromatous leprosy, seven were diagnosed with lepromatous, and one was diagnosed with borderline tuberculoid leprosy. Patients were symptomatic with arthritis for a median of 5.3 years before HD diagnosis. Sixty-two percent of patients (11) were diagnosed with rheumatoid arthritis (RA) before HD diagnosis, and 10 of which were seronegative RA. Hands, feet, wrists, and elbows were most commonly reported as affected joints. Over half of the patients (61%) had completed HD multidrug therapy at the time of review, and 73% of these subjects had persistent joint pain requiring steroids or methotrexate for symptomatic control. Chronic arthritis in HD patients is present in a series of US-acquired cases of HD. Arthritis did not resolve with successful treatment of HD in most cases.


Assuntos
Artrite Reumatoide/diagnóstico , Hanseníase/diagnóstico , Idoso , Antirreumáticos/uso terapêutico , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Clofazimina/uso terapêutico , Estudos Cross-Over , Quimioterapia Combinada , Feminino , Humanos , Hansenostáticos/uso terapêutico , Hanseníase/complicações , Hanseníase/tratamento farmacológico , Masculino , Metotrexato/uso terapêutico , Mycobacterium leprae/isolamento & purificação , Estudos Retrospectivos , Rifampina/uso terapêutico , Pele/efeitos dos fármacos , Pele/microbiologia , Esteroides/uso terapêutico , Talidomida/uso terapêutico , Estados Unidos
3.
Artigo em Inglês | MEDLINE | ID: mdl-27643542

RESUMO

BACKGROUND: The skin is one of the most affected organs in tuberous sclerosis complex and angiofibromas are seen in almost 80% of such patients. These benign tumors impose a great psycho-social burden on patients. OBJECTIVE: The aim of the study was to evaluate the effectiveness and tolerability of topical sirolimus for facial angiofibromas in patients with tuberous sclerosis complex. METHODS: This was a prospective, single-blinded, cross-over study which involved twelve patients. We investigated the effect and safety of topical 0.1% sirolimus, which was obtained by crushing sirolimus tablets and mixing it with petrolatum. The patients were asked to apply the cream to one side of their face, and vaseline to the other side. The effect of topical sirolimus was evaluated using the "facial angiofibroma severity index." RESULTS: There was a significant improvement in the redness and extension of the tumors on the sides to which the active ingredient was applied. Some side effects such as itching and irritation occurred in three patients, which were treated with topical hydrocortisone cream. CONCLUSION: Topical sirolimus appears to be a promising, fairly well tolerated treatment for facial angiofibromas in patients with tuberous sclerosis complex. Although its efficacy diminishes with time, repetitive usage is effective.


Assuntos
Angiofibroma/diagnóstico , Angiofibroma/tratamento farmacológico , Antibióticos Antineoplásicos/administração & dosagem , Sirolimo/administração & dosagem , Esclerose Tuberosa/diagnóstico , Esclerose Tuberosa/tratamento farmacológico , Administração Tópica , Criança , Estudos Cross-Over , Feminino , Humanos , Masculino , Estudos Prospectivos , Método Simples-Cego , Resultado do Tratamento
4.
Clin Pharmacol Ther ; 90(1): 100-8, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21562488

RESUMO

Systemic and oral clearances of alfentanil (ALF) are in vivo probes for hepatic and first-pass cytochrome P450 (CYP) 3A. Both ALF single-point plasma concentrations and miosis are surrogates for area under the concentration-time curve (AUC) and clearance and are minimal and noninvasive CYP3A probes. This investigation determined ALF sensitivity for detecting graded CYP3A induction and compared it with that of midazolam (MDZ). Twelve volunteers (sequential crossover) received 0, 5, 10, 25, or 75 mg oral rifampin for 5 days. MDZ and ALF were given intravenously and orally on sequential days. Dark-adapted pupil diameter was measured with blood sampling. Graded rifampin decreased plasma MDZ AUCs to 83, 76, 62, and 59% (intravenous (i.v.)) and 78, 66, 39, and 24% (oral) of control. Hepatic and first-pass CYP3A induction were detected comparably by plasma MDZ and ALF AUCs. Single ALF concentrations detected all CYP3A induction, whereas MDZ was less sensitive. ALF miosis detected induction of first-pass but not hepatic CYP3A.


Assuntos
Alfentanil/farmacologia , Analgésicos Opioides/farmacologia , Citocromo P-450 CYP3A/biossíntese , Fígado/efeitos dos fármacos , Fígado/enzimologia , Miose/induzido quimicamente , Administração Oral , Adolescente , Adulto , Alfentanil/administração & dosagem , Analgésicos Opioides/administração & dosagem , Área Sob a Curva , Disponibilidade Biológica , Estudos Cross-Over , Indução Enzimática/efeitos dos fármacos , Feminino , Meia-Vida , Humanos , Hipnóticos e Sedativos/sangue , Hipnóticos e Sedativos/farmacologia , Injeções Intravenosas , Cinética , Hansenostáticos/farmacologia , Masculino , Midazolam/sangue , Midazolam/farmacologia , Rifampina/farmacologia , Fumar/metabolismo , Adulto Jovem
5.
Clin Pharmacokinet ; 46(8): 697-712, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17655376

RESUMO

BACKGROUND: Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris; however, the oral formulation is known to cause dose-dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen's disease. A gel formulation of dapsone was recently developed to treat acne vulgaris. As dapsone is administered topically, it was expected that systemic absorption would be considerably lower than that observed with oral dapsone therapy, thereby avoiding any adverse haematological effects. OBJECTIVE: To report the pharmacokinetic profile of topically applied dapsone gel, 5% in the treatment of acne vulgaris. STUDY PARTICIPANTS AND METHODS: Three prospective, open-label studies enrolled a total of 548 subjects with acne vulgaris: two phase I pharmacokinetic studies (crossover and drug interaction) and one phase III long-term safety study. In the crossover study (n = 18), topical dapsone gel applied twice daily for a total of 14 days to 22.5% of the body surface area was compared with a single dose of oral dapsone 100mg (the typical clinical dose). In the drug-interaction study (n = 24), oral trimethoprim/sulfamethoxazole monotherapy, topical dapsone gel monotherapy and the two in combination were used twice daily for 7, 21 and 7 days, respectively. In the long-term safety study (n = 506), topical dapsone gel was applied twice daily to acne-affected areas for up to 12 months. Blood samples were drawn at various timepoints in each study to assess drug and metabolite concentrations. Systemic concentrations of dapsone, N-acetyl dapsone, dapsone hydroxylamine, trimethoprim and sulfamethoxazole were determined, according to the study design. RESULTS: In the crossover study, the mean area under the plasma concentration-time curve (AUC) from 0 to 24 hours for dapsone was 417.5 ng x h/mL after 2 weeks of dapsone gel therapy (n = 10), compared with an AUC from time zero to infinity of 52,641 ng x h/mL after a single dose of oral dapsone; this represents a 126-fold lower systemic exposure for dapsone gel at typical therapeutic doses. In the drug-interaction study, the AUC from 0 to 12 hours for dapsone was 221.52 ng x h/mL after 3 weeks of dapsone gel monotherapy compared with 320.3 ng x h/mL after 1 week of coadministration with trimethoprim/sulfamethoxazole. In the long-term safety study, the mean plasma dapsone concentrations ranged from 7.5 to 11 ng/mL over 12 months. Overall, total systemic exposures to dapsone and its metabolites were approximately 100-fold less for dapsone gel than for oral dapsone, even in the presence of trimethoprim/sulfamethoxazole. There were no reports of any haematological adverse events. CONCLUSIONS: Topical application of dapsone gel in various settings ranging from 2 weeks to 12 months resulted in systemic exposures to dapsone and its metabolites that were approximately 100-fold less than those after oral dapsone at a therapeutic dose level. The concentrations of dapsone and its metabolites reached steady state and did not increase during prolonged treatment.


Assuntos
Acne Vulgar/tratamento farmacológico , Dapsona/farmacocinética , Adolescente , Adulto , Anti-Infecciosos , Área Sob a Curva , Criança , Estudos Cross-Over , Dapsona/administração & dosagem , Dapsona/sangue , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Géis , Humanos , Estudos Longitudinais , Masculino , Farmacocinética
6.
Tuberculosis (Edinb) ; 84(6): 365-73, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15525560

RESUMO

BACKGROUND: Clofazimine is potentially useful for the treatment of disease due to multidrug resistant Mycobacterium tuberculosis, as well as leprosy and certain chronic skin diseases. Its pharmacokinetics have been incompletely characterized. This study was conducted to explore issues relating to bioavailability in the presence of food, orange juice, and antacid. METHODS: A 5 drug regimen consisting of clofazimine, cycloserine, ethionamide, para-aminosalicyclic acid, and pyridoxime was administered to healthy subjects four times using a four period cross-over design with two weeks washout between treatments. Subjects also received orange juice, a high fat meal, aluminum/magnesium antacid, or only water in random order with the drug regimen. The pharmacokinetics of clofazimine were assessed using individual- and population-based methods and relative bioavailability compared to fasting administration was determined. RESULTS: Clofazimine exhibited a sometimes prolonged and variable lag-time and considerable variability in plasma concentrations. From the population analysis (one-compartment model), the mean oral clearance was 76.7 l/h (CV=74.2%) and mean apparent volume of distribution was 1470 l (CV=36.3%). The first-order absorption rate constant ranged from 0.716 to 1.33 h(-1) (pooled CV=61.7%). Residual (proportional) error was 49.1%. Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid. CONCLUSION: Administration of clofazimine with a high fat meal provides the greatest bioavailability, however, bioavailability is associated with high inter- and intra-subject variability. Both orange juice and aluminum-magnesium antacid produced a reduction in mean bioavailability of clofazimine.


Assuntos
Antiácidos/metabolismo , Bebidas , Clofazimina/farmacocinética , Alimentos , Hansenostáticos/farmacocinética , Administração Oral , Adulto , Ácido Aminossalicílico/administração & dosagem , Antituberculosos/administração & dosagem , Disponibilidade Biológica , Citrus sinensis , Clofazimina/sangue , Estudos Cross-Over , Ciclosserina/administração & dosagem , Gorduras na Dieta , Combinação de Medicamentos , Interações Medicamentosas , Etionamida/administração & dosagem , Interações Alimento-Droga , Humanos , Hansenostáticos/sangue , Piridoxina/administração & dosagem
7.
J Clin Pharmacol ; 39(11): 1162-8, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10579147

RESUMO

Thalidomide was recently approved in the United States for the treatment of erythema nodosum leprosum, a complication of leprosy. The present study determined the bioequivalence and pharmacokinetics of Celgene's commercial and clinical trial thalidomide formulations and the Brazilian Tortuga formulation in an open-label, single-dose, three-way crossover design. Seventeen healthy subjects were given 200 mg of thalidomide on three occasions, and blood samples were collected over 48 hours. Pharmacokinetic parameters were determined using compartmental methods for the two Celgene formulations and using noncompartmental methods for all three formulations. All subjects reported adverse events, none of which was serious or unexpected. Celgene formulations were bioequivalent when comparing Cmax, tmax, and AUC. There was significant variability in plasma levels from the Tortuga formulation, giving a mean profile that was distinctly different from the two Celgene formulations with a lower Cmax value and a longer terminal phase. The lower Cmax was probably due to slower absorption. The terminal rate constant for the Tortuga formulation was significantly less, giving rise to a terminal half-life of 15 hours compared to about 5 to 6 hours for the Celgene formulations. Confidence intervals for Cmax between the Tortuga and the Celgene formulations were outside the 80% to 125% range, indicating a lack of bioequivalence. Extent of absorption, as measured by AUC0-infinity, was approximately equal for all three formulations. Terminal half-life for Tortuga was two to three times longer compared to the Celgene formulations and is clear evidence for absorption rate limitations. The two Celgene formulations showed similar pharmacokinetic parameters with profiles that were best described by a one-compartment model with first-order absorption and elimination. The authors conclude that Celgene's clinical trial and commercial thalidomide formulations are similar to each other and distinctly different from the Tortuga formulation and that all three formulations exhibited absorption rate-limited elimination.


Assuntos
Hansenostáticos/farmacocinética , Talidomida/farmacocinética , Adulto , Estudos Cross-Over , Jejum , Humanos , Hansenostáticos/efeitos adversos , Hansenostáticos/sangue , Masculino , Modelos Biológicos , Talidomida/efeitos adversos , Talidomida/sangue , Equivalência Terapêutica , Fatores de Tempo
8.
Clin Pharmacol Ther ; 65(5): 483-90, 1999 May.
Artigo em Inglês | MEDLINE | ID: mdl-10340913

RESUMO

OBJECTIVES: To determine the single- and multiple-dose pharmacokinetics of oral thalidomide (200 mg/day, administered for 21 days) and to assess the effects of steady-state plasma concentrations of thalidomide on the single-dose pharmacokinetics of ethinyl estradiol (INN, ethinylestradiol) and norethindrone (INN, norethisterone). METHODS: A randomized, 2-period crossover study was performed in 10 healthy premenopausal female volunteers. The pharmacokinetic profiles of plasma concentrations of thalidomide were evaluated with both noncompartmental and compartmental methods, whereas those of ethinyl estradiol and norethindrone were calculated with noncompartmental methods. The effects of steady-state plasma thalidomide concentrations on the pharmacokinetics of ethinyl estradiol and norethindrone were determined with use of an ANOVA model that included treatment sequence, subject within sequence, period, and treatment as factors. RESULTS: Thalidomide plasma concentrations were best predicted by a 1-compartment model with first-order absorption and elimination and an absorption time-lag. There were no significant differences between pharmacokinetic parameters for thalidomide after 1 dose and those after 18 consecutive doses. Except for a minor decrease of the elimination rate constant (k(e)) for ethinyl estradiol, coadministration of thalidomide had no significant effects on the pharmacokinetic profiles for either ethinyl estradiol or norethindrone. The change in k(e) for ethinyl estradiol during thalidomide administration was not associated with any alteration in the clearance or elimination half-life for this hormone. CONCLUSIONS: Multiple-dose pharmacokinetics of thalidomide is similar to the single-dose profile. This study did not investigate the efficacy of the 21-day fixed ethinyl estradiol-norethindrone regimen, but the results suggest that thalidomide is unlikely to affect the pharmacokinetics of orally administered hormonal contraceptives.


Assuntos
Antineoplásicos Hormonais/farmacocinética , Anticoncepcionais Orais Sintéticos/farmacocinética , Etinilestradiol/farmacocinética , Noretindrona/farmacocinética , Talidomida/farmacologia , Talidomida/farmacocinética , Administração Oral , Adulto , Área Sob a Curva , Estudos Cross-Over , Fármacos Dermatológicos/farmacocinética , Fármacos Dermatológicos/farmacologia , Esquema de Medicação , Feminino , Meia-Vida , Humanos , Hipnóticos e Sedativos/farmacocinética , Hipnóticos e Sedativos/farmacologia , Hansenostáticos/farmacocinética , Hansenostáticos/farmacologia , Valores de Referência , Talidomida/administração & dosagem , Talidomida/sangue
9.
J Wound Care ; 5(9): 406-11, 1996 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8954434

RESUMO

A controlled trial was implemented to investigate the hypothesis that plantar ulcer sites associated with leprosy, in subjects who were supplied with foot orthoses, would heal more quickly than those in a control group. The population was comprised of individuals with impairments associated with leprosy, living near a leprosy hospital in India. Ulcer area was compared in the two groups and assessed at three-monthly intervals from July 1993 to March 1994. At the March 1994 assessment 58% of ulcers in the experimental group had healed but only 14% in the control group. At this point patients in the control group were supplied with orthoses and three months later, in June 1994, 60% of the ulcers in the experimental group and 62% of ulcers in the control group had healed. The results of this study demonstrate that orthotic intervention can significantly reduce the duration of ulceration.


Assuntos
Úlcera do Pé/microbiologia , Úlcera do Pé/terapia , Hanseníase/complicações , Aparelhos Ortopédicos/normas , Adulto , Estudos Cross-Over , Feminino , Humanos , Masculino , Índice de Gravidade de Doença , Cicatrização
10.
Indian J Lepr ; 68(2): 149-53, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8835583

RESUMO

Leprosy is transmitted by dissemination of M.leprae which are lodged in the nose of the patients suffering from multibacillary (MB) type of the disease. Rifampicin, a potent bactericidal antileprotic drug is given orally to the patients with a view to make the infective cases non-infective. Earlier work by us has shown that intranasal administration of rifampicin helps in reducing the M.leprae load in the nose much faster than after conventional oral administration. In the present study, rifampicin concentrations in plasma/urine/nasal wash of healthy volunteers following oral and intranasal administration were determined. Following intranasal administration, rifampicin was not detectable in plasma and high concentrations were measured in the nasal wash. Following oral administration, rifampicin was not detectable in the nasal wash indicating that enough antibiotic levels are not available for clearing M.leprae from nose.


Assuntos
Hansenostáticos/farmacocinética , Rifampina/farmacocinética , Administração Intranasal , Administração Oral , Adulto , Estudos Cross-Over , Humanos , Hansenostáticos/administração & dosagem , Hanseníase/prevenção & controle , Hanseníase/transmissão , Masculino , Líquido da Lavagem Nasal/química , Mucosa Nasal/metabolismo , Rifampina/administração & dosagem
11.
s.l; s.n; 1996. 6 p. ilus, tab, graf.
Não convencional em Inglês | SES-SP, HANSEN, HANSENIASE, SESSP-ILSLACERVO, SES-SP | ID: biblio-1238433
12.
Nephron ; 67(3): 270-3, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-7936015

RESUMO

Our observation that thalidomide administration to a dialysis patient with leprosy alleviated his pruritus led us to conduct this short-term study to assess the efficacy of the drug in this regard. From 210 hemodialysis patients, 29 cases of refractory uremic pruritus were entered into the study. Patients were instructed to score their symptoms from 0 to 3, three times a day and assigned to receive thalidomide or placebo at bed time for 7 days. After a washout period of 7 days, drugs were crossed over. Response was defined as a reduction of at least 50% in the pruritus scoring. Eighteen patients finished the study. In the first phase, 55% of patients responded showing a mean reduction in their pruritus scoring of 78% (p < 0.05 vs. placebo); no response to placebo was observed. A similar proportion of patients responded to thalidomide in the second phase with a mean reduction in their pruritus scoring of 81%. In conclusion, thalidomide can be a precious tool in the handling of uremic pruritus unresponsive to available therapy.


Assuntos
Falência Renal Crônica/terapia , Prurido/tratamento farmacológico , Talidomida/uso terapêutico , Idoso , Estudos Cross-Over , Esquema de Medicação , Feminino , Humanos , Falência Renal Crônica/complicações , Masculino , Pessoa de Meia-Idade , Prurido/etiologia , Prurido/patologia , Diálise Renal , Talidomida/administração & dosagem , Uremia/complicações , Uremia/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA